Loading…
The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance
Inflammation at the level of the β cell appears to be involved in progressive β‐cell dysfunction in type 2 diabetes. We assessed the effect of blocking interleukin‐1 (IL‐1) by anakinra [recombinant human interleukin‐1 receptor antagonist (IL‐1Ra)] on β‐cell function. Sixteen participants with impair...
Saved in:
Published in: | Diabetes, obesity & metabolism obesity & metabolism, 2014-12, Vol.16 (12), p.1269-1273 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c5227-7f7fff23e344df86c01dfc0a5782ff6b1c8c9e28b425270994411e2ab08c48fa3 |
---|---|
cites | cdi_FETCH-LOGICAL-c5227-7f7fff23e344df86c01dfc0a5782ff6b1c8c9e28b425270994411e2ab08c48fa3 |
container_end_page | 1273 |
container_issue | 12 |
container_start_page | 1269 |
container_title | Diabetes, obesity & metabolism |
container_volume | 16 |
creator | van Poppel, P. C. M. van Asseldonk, E. J. P. Holst, J. J. Vilsbøll, T. Netea, M. G. Tack, C. J. |
description | Inflammation at the level of the β cell appears to be involved in progressive β‐cell dysfunction in type 2 diabetes. We assessed the effect of blocking interleukin‐1 (IL‐1) by anakinra [recombinant human interleukin‐1 receptor antagonist (IL‐1Ra)] on β‐cell function. Sixteen participants with impaired glucose tolerance were treated with 150 mg anakinra daily for 4 weeks in a double blind, randomized, placebo‐controlled cross‐over study with a wash‐out period of 4 weeks. At the end of each treatment period, oral glucose tolerance tests (OGTTs) and hyperglycaemic clamps were performed. First‐phase insulin secretion improved after anakinra treatment compared with placebo, 148 ± 20 versus 123 ± 14 mU/l, respectively (p = 0.03), and the insulinogenic index was higher after anakinra treatment. These results support the concept of involvement of IL‐1β in the (progressive) decrease of insulin secretion capacity associated with type 2 diabetes. |
doi_str_mv | 10.1111/dom.12357 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1654684713</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1622596927</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5227-7f7fff23e344df86c01dfc0a5782ff6b1c8c9e28b425270994411e2ab08c48fa3</originalsourceid><addsrcrecordid>eNqNkstu1DAUhiMEohdY8AIoEhu6SOtr7CzRFAak0kpQBDvLcY5nPM3EU9uh7aPwtjidThdIILzxsf2dTzryXxSvMDrGeZ10fn2MCeXiSbGPWU0rTEn99L4mlWwQ2SsOYlwhhBiV4nmxRziiDcVyv_h1uYTSDQlCD-OVGypcBjCwST6Uekh64QcXUy51fgy6dOtN8D8hltaFmKrNUsepP469G8oIJkByfsh8t7v1CxicyacObssJGtsVmBTLG5eWk0-7AF256Efjsyv5HoIeDLwonlndR3j5sB8W3z68v5x9rM4u5p9m784qwwkRlbDCWksoUMY6K2uDcGcN0lxIYm3dYiNNA0S2jHAiUNMwhjEQ3SJpmLSaHhZvt9482PUIMam1iwb6Xg_gx6hwzVktmcD0P1BCeFM3RGT0zR_oyo9hyIMoinjDOKrFP6nJhQjiAmXqaEuZ4GMMYNUmuLUOdwojNQVA5QCo-wBk9vWDcWzX0D2Sux_PwMkWuHE93P3dpE4vPu-U1bYjBwFuHzt0uFK1oIKr7-dzNZ99nZ2f_viiGP0NUBTLMw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1622020570</pqid></control><display><type>article</type><title>The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>van Poppel, P. C. M. ; van Asseldonk, E. J. P. ; Holst, J. J. ; Vilsbøll, T. ; Netea, M. G. ; Tack, C. J.</creator><creatorcontrib>van Poppel, P. C. M. ; van Asseldonk, E. J. P. ; Holst, J. J. ; Vilsbøll, T. ; Netea, M. G. ; Tack, C. J.</creatorcontrib><description>Inflammation at the level of the β cell appears to be involved in progressive β‐cell dysfunction in type 2 diabetes. We assessed the effect of blocking interleukin‐1 (IL‐1) by anakinra [recombinant human interleukin‐1 receptor antagonist (IL‐1Ra)] on β‐cell function. Sixteen participants with impaired glucose tolerance were treated with 150 mg anakinra daily for 4 weeks in a double blind, randomized, placebo‐controlled cross‐over study with a wash‐out period of 4 weeks. At the end of each treatment period, oral glucose tolerance tests (OGTTs) and hyperglycaemic clamps were performed. First‐phase insulin secretion improved after anakinra treatment compared with placebo, 148 ± 20 versus 123 ± 14 mU/l, respectively (p = 0.03), and the insulinogenic index was higher after anakinra treatment. These results support the concept of involvement of IL‐1β in the (progressive) decrease of insulin secretion capacity associated with type 2 diabetes.</description><identifier>ISSN: 1462-8902</identifier><identifier>EISSN: 1463-1326</identifier><identifier>DOI: 10.1111/dom.12357</identifier><identifier>PMID: 25039318</identifier><identifier>CODEN: DOMEF6</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Beta cells ; Blood Glucose - drug effects ; Cross-Over Studies ; Diabetes ; diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - drug therapy ; Double-Blind Method ; drug mechanism ; experimental pharmacology ; Female ; Glucose Intolerance - blood ; Glucose Intolerance - drug therapy ; Glucose tolerance ; Glucose Tolerance Test ; Humans ; Hypoglycemic Agents - administration & dosage ; Hypoglycemic Agents - therapeutic use ; Insulin - metabolism ; Insulin Secretion ; Insulin-Secreting Cells - drug effects ; Insulin-Secreting Cells - metabolism ; Interleukin 1 receptor antagonist ; Interleukin 1 Receptor Antagonist Protein - administration & dosage ; Interleukin 1 Receptor Antagonist Protein - therapeutic use ; Male ; Middle Aged ; Placebos ; Receptors, Interleukin-1 - antagonists & inhibitors ; Treatment Outcome ; type 2 diabetes ; β cell</subject><ispartof>Diabetes, obesity & metabolism, 2014-12, Vol.16 (12), p.1269-1273</ispartof><rights>2014 John Wiley & Sons Ltd</rights><rights>2014 John Wiley & Sons Ltd.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5227-7f7fff23e344df86c01dfc0a5782ff6b1c8c9e28b425270994411e2ab08c48fa3</citedby><cites>FETCH-LOGICAL-c5227-7f7fff23e344df86c01dfc0a5782ff6b1c8c9e28b425270994411e2ab08c48fa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25039318$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Poppel, P. C. M.</creatorcontrib><creatorcontrib>van Asseldonk, E. J. P.</creatorcontrib><creatorcontrib>Holst, J. J.</creatorcontrib><creatorcontrib>Vilsbøll, T.</creatorcontrib><creatorcontrib>Netea, M. G.</creatorcontrib><creatorcontrib>Tack, C. J.</creatorcontrib><title>The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance</title><title>Diabetes, obesity & metabolism</title><addtitle>Diabetes Obes Metab</addtitle><description>Inflammation at the level of the β cell appears to be involved in progressive β‐cell dysfunction in type 2 diabetes. We assessed the effect of blocking interleukin‐1 (IL‐1) by anakinra [recombinant human interleukin‐1 receptor antagonist (IL‐1Ra)] on β‐cell function. Sixteen participants with impaired glucose tolerance were treated with 150 mg anakinra daily for 4 weeks in a double blind, randomized, placebo‐controlled cross‐over study with a wash‐out period of 4 weeks. At the end of each treatment period, oral glucose tolerance tests (OGTTs) and hyperglycaemic clamps were performed. First‐phase insulin secretion improved after anakinra treatment compared with placebo, 148 ± 20 versus 123 ± 14 mU/l, respectively (p = 0.03), and the insulinogenic index was higher after anakinra treatment. These results support the concept of involvement of IL‐1β in the (progressive) decrease of insulin secretion capacity associated with type 2 diabetes.</description><subject>Beta cells</subject><subject>Blood Glucose - drug effects</subject><subject>Cross-Over Studies</subject><subject>Diabetes</subject><subject>diabetes mellitus</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Double-Blind Method</subject><subject>drug mechanism</subject><subject>experimental pharmacology</subject><subject>Female</subject><subject>Glucose Intolerance - blood</subject><subject>Glucose Intolerance - drug therapy</subject><subject>Glucose tolerance</subject><subject>Glucose Tolerance Test</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin - metabolism</subject><subject>Insulin Secretion</subject><subject>Insulin-Secreting Cells - drug effects</subject><subject>Insulin-Secreting Cells - metabolism</subject><subject>Interleukin 1 receptor antagonist</subject><subject>Interleukin 1 Receptor Antagonist Protein - administration & dosage</subject><subject>Interleukin 1 Receptor Antagonist Protein - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Placebos</subject><subject>Receptors, Interleukin-1 - antagonists & inhibitors</subject><subject>Treatment Outcome</subject><subject>type 2 diabetes</subject><subject>β cell</subject><issn>1462-8902</issn><issn>1463-1326</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNqNkstu1DAUhiMEohdY8AIoEhu6SOtr7CzRFAak0kpQBDvLcY5nPM3EU9uh7aPwtjidThdIILzxsf2dTzryXxSvMDrGeZ10fn2MCeXiSbGPWU0rTEn99L4mlWwQ2SsOYlwhhBiV4nmxRziiDcVyv_h1uYTSDQlCD-OVGypcBjCwST6Uekh64QcXUy51fgy6dOtN8D8hltaFmKrNUsepP469G8oIJkByfsh8t7v1CxicyacObssJGtsVmBTLG5eWk0-7AF256Efjsyv5HoIeDLwonlndR3j5sB8W3z68v5x9rM4u5p9m784qwwkRlbDCWksoUMY6K2uDcGcN0lxIYm3dYiNNA0S2jHAiUNMwhjEQ3SJpmLSaHhZvt9482PUIMam1iwb6Xg_gx6hwzVktmcD0P1BCeFM3RGT0zR_oyo9hyIMoinjDOKrFP6nJhQjiAmXqaEuZ4GMMYNUmuLUOdwojNQVA5QCo-wBk9vWDcWzX0D2Sux_PwMkWuHE93P3dpE4vPu-U1bYjBwFuHzt0uFK1oIKr7-dzNZ99nZ2f_viiGP0NUBTLMw</recordid><startdate>201412</startdate><enddate>201412</enddate><creator>van Poppel, P. C. M.</creator><creator>van Asseldonk, E. J. P.</creator><creator>Holst, J. J.</creator><creator>Vilsbøll, T.</creator><creator>Netea, M. G.</creator><creator>Tack, C. J.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201412</creationdate><title>The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance</title><author>van Poppel, P. C. M. ; van Asseldonk, E. J. P. ; Holst, J. J. ; Vilsbøll, T. ; Netea, M. G. ; Tack, C. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5227-7f7fff23e344df86c01dfc0a5782ff6b1c8c9e28b425270994411e2ab08c48fa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Beta cells</topic><topic>Blood Glucose - drug effects</topic><topic>Cross-Over Studies</topic><topic>Diabetes</topic><topic>diabetes mellitus</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Double-Blind Method</topic><topic>drug mechanism</topic><topic>experimental pharmacology</topic><topic>Female</topic><topic>Glucose Intolerance - blood</topic><topic>Glucose Intolerance - drug therapy</topic><topic>Glucose tolerance</topic><topic>Glucose Tolerance Test</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin - metabolism</topic><topic>Insulin Secretion</topic><topic>Insulin-Secreting Cells - drug effects</topic><topic>Insulin-Secreting Cells - metabolism</topic><topic>Interleukin 1 receptor antagonist</topic><topic>Interleukin 1 Receptor Antagonist Protein - administration & dosage</topic><topic>Interleukin 1 Receptor Antagonist Protein - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Placebos</topic><topic>Receptors, Interleukin-1 - antagonists & inhibitors</topic><topic>Treatment Outcome</topic><topic>type 2 diabetes</topic><topic>β cell</topic><toplevel>online_resources</toplevel><creatorcontrib>van Poppel, P. C. M.</creatorcontrib><creatorcontrib>van Asseldonk, E. J. P.</creatorcontrib><creatorcontrib>Holst, J. J.</creatorcontrib><creatorcontrib>Vilsbøll, T.</creatorcontrib><creatorcontrib>Netea, M. G.</creatorcontrib><creatorcontrib>Tack, C. J.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes, obesity & metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Poppel, P. C. M.</au><au>van Asseldonk, E. J. P.</au><au>Holst, J. J.</au><au>Vilsbøll, T.</au><au>Netea, M. G.</au><au>Tack, C. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance</atitle><jtitle>Diabetes, obesity & metabolism</jtitle><addtitle>Diabetes Obes Metab</addtitle><date>2014-12</date><risdate>2014</risdate><volume>16</volume><issue>12</issue><spage>1269</spage><epage>1273</epage><pages>1269-1273</pages><issn>1462-8902</issn><eissn>1463-1326</eissn><coden>DOMEF6</coden><abstract>Inflammation at the level of the β cell appears to be involved in progressive β‐cell dysfunction in type 2 diabetes. We assessed the effect of blocking interleukin‐1 (IL‐1) by anakinra [recombinant human interleukin‐1 receptor antagonist (IL‐1Ra)] on β‐cell function. Sixteen participants with impaired glucose tolerance were treated with 150 mg anakinra daily for 4 weeks in a double blind, randomized, placebo‐controlled cross‐over study with a wash‐out period of 4 weeks. At the end of each treatment period, oral glucose tolerance tests (OGTTs) and hyperglycaemic clamps were performed. First‐phase insulin secretion improved after anakinra treatment compared with placebo, 148 ± 20 versus 123 ± 14 mU/l, respectively (p = 0.03), and the insulinogenic index was higher after anakinra treatment. These results support the concept of involvement of IL‐1β in the (progressive) decrease of insulin secretion capacity associated with type 2 diabetes.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>25039318</pmid><doi>10.1111/dom.12357</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1462-8902 |
ispartof | Diabetes, obesity & metabolism, 2014-12, Vol.16 (12), p.1269-1273 |
issn | 1462-8902 1463-1326 |
language | eng |
recordid | cdi_proquest_miscellaneous_1654684713 |
source | Wiley-Blackwell Read & Publish Collection |
subjects | Beta cells Blood Glucose - drug effects Cross-Over Studies Diabetes diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Double-Blind Method drug mechanism experimental pharmacology Female Glucose Intolerance - blood Glucose Intolerance - drug therapy Glucose tolerance Glucose Tolerance Test Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - therapeutic use Insulin - metabolism Insulin Secretion Insulin-Secreting Cells - drug effects Insulin-Secreting Cells - metabolism Interleukin 1 receptor antagonist Interleukin 1 Receptor Antagonist Protein - administration & dosage Interleukin 1 Receptor Antagonist Protein - therapeutic use Male Middle Aged Placebos Receptors, Interleukin-1 - antagonists & inhibitors Treatment Outcome type 2 diabetes β cell |
title | The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T05%3A53%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20interleukin-1%20receptor%20antagonist%20anakinra%20improves%20first-phase%20insulin%20secretion%20and%20insulinogenic%20index%20in%20subjects%20with%20impaired%20glucose%20tolerance&rft.jtitle=Diabetes,%20obesity%20&%20metabolism&rft.au=van%20Poppel,%20P.%20C.%20M.&rft.date=2014-12&rft.volume=16&rft.issue=12&rft.spage=1269&rft.epage=1273&rft.pages=1269-1273&rft.issn=1462-8902&rft.eissn=1463-1326&rft.coden=DOMEF6&rft_id=info:doi/10.1111/dom.12357&rft_dat=%3Cproquest_cross%3E1622596927%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5227-7f7fff23e344df86c01dfc0a5782ff6b1c8c9e28b425270994411e2ab08c48fa3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1622020570&rft_id=info:pmid/25039318&rfr_iscdi=true |